case study discussion gynecologic health

Log in using your username and password

• Search More Search for this keyword Advanced search
• Latest content
• Global health
• BMJ Journals More You are viewing from: Google Indexer

You are here

• Obstetrics and gynaecology
• Partial Molar Ectopic Pregnancy: A diagnostic challenge Vinodhini Kadirvel , Sweta Singh , Suvendu Purkait , Mohammed Shahin BMJ Case Reports CP Apr 2024, 17 (4) e255432; DOI: 10.1136/bcr-2023-255432
• From endometrium to fingernail bed: histological evaluation of a rare cutaneous metastasis Simona A Alomary , Robert A Schwartz , W Clark Lambert , Albert Alhatem BMJ Case Reports CP Apr 2024, 17 (4) e259545; DOI: 10.1136/bcr-2023-259545
• Fertility-sparing approach in concurrent gliomatosis peritonei and growing teratoma syndrome in a young woman Siti Nawwal Ahmad Nasfy , Habibah Abdul Hamid , Azalea Md Khairuddin , Maryam Kameelah Mohamad Fauzi BMJ Case Reports CP Apr 2024, 17 (4) e257326; DOI: 10.1136/bcr-2023-257326
• Vaginal pessary: a culprit for intraperitoneal bladder perforation Ankit Gupta , Chandrakala Channappa , Mohamed Abdelkhalek Ramadan Ibrahim Elsheikh , Manjula Annappa BMJ Case Reports CP Apr 2024, 17 (4) e257233; DOI: 10.1136/bcr-2023-257233
• Aggressive precursor B cell ALL of cervix with obstructive uropathy Anupama Bahadur , Rajlaxmi Mundhra , Poonam Gill , Ashok Singh BMJ Case Reports CP Apr 2024, 17 (4) e258313; DOI: 10.1136/bcr-2023-258313
• Submucous leiomyoma: an uncommon cause of heavy menstrual bleeding in early adolescence Daniela Agostinho David , Ângela Reis Rodrigues , João Amaral , Fernanda Geraldes BMJ Case Reports CP Mar 2024, 17 (3) e258426; DOI: 10.1136/bcr-2023-258426
• A rare cause of oligomenorrhoea Vijayakumar Karthik , Puthiyaveetil Khadar Jabbar , Srikumar Sriharii , Sarayu Soumya BMJ Case Reports CP Mar 2024, 17 (3) e259730; DOI: 10.1136/bcr-2024-259730
• First intrauterine transfusion in Rh isoimmunised triplet pregnancy Vandana Bansal , Akshaykumar Babanrao Gangurde , Amol Pawar , Forum Shah BMJ Case Reports CP Mar 2024, 17 (3) e258242; DOI: 10.1136/bcr-2023-258242
• Myomatous erythrocytosis syndrome: a uterine fibroid associated with polycythaemia Faisal Ansari , Talal Al Assil , Mohammad Omaira , Anna V Hoekstra BMJ Case Reports CP Mar 2024, 17 (3) e256927; DOI: 10.1136/bcr-2023-256927
• Management of an acute intracranial emergency in pregnancy Petronella Brokkelkamp , Jelle H Baalman , Maarten J Driesse , Kuan H Kho BMJ Case Reports CP Mar 2024, 17 (3) e258066; DOI: 10.1136/bcr-2023-258066
• Anaesthesia (209)
• Cardiovascular medicine (985)
• Complementary medicine (6)
• Dentistry and oral medicine (211)
• Dermatology (537)
• Clinical diagnostic tests (50)
• Radiology (diagnostics) (146)
• Surgical diagnostic tests (23)
• Diagnostics
• Drugs and medicines (1781)
• Ear, nose and throat/otolaryngology (451)
• Disaster response
• Poisoning (49)
• Resuscitation (57)
• Trauma (160)
• Emergency medicine (473)
• Adrenal disorders (118)
• Calcium and bone (97)
• Diabetes (127)
• Drugs: endocrine system (25)
• Lipid disorders (26)
• Metabolic disorders (89)
• Pituitary disorders (57)
• Thyroid disease (118)
• Endocrinology (652)
• Changing physician behavior
• Effectiveness of care
• Gastroenterology (913)
• Drugs: gastrointestinal system (44)
• Endoscopy (165)
• GI bleeding (99)
• Infection (gastroenterology) (107)
• Inflammatory bowel disease (72)
• Liver disease (186)
• Neurogastroenterology
• Oesophagus (55)
• Pancreas and biliary tract (100)
• Pancreatitis (61)
• Portal hypertension (16)
• Small intestine (76)
• Stomach and duodenum (85)
• General practice / family medicine (242)
• Clinical genetics
• Cytogenetics
• Genetic screening / counselling (92)
• Molecular genetics
• Genetics (291)
• Elder abuse
• End of life decisions (geriatric medicine) (2)
• Long term care (18)
• Psychogeriatrics
• Geriatric medicine (65)
• Haematology (incl blood transfusion) (531)
• HIV/AIDS (80)
• Immunology (including allergy) (56)
• Infectious diseases (1321)
• Adult intensive care (301)
• Mechanical ventilation (19)
• Neonatal intensive care (90)
• Paediatric intensive care (69)
• Intensive care (560)
• Brain stem / cerebellum (85)
• Cerebral palsy (6)
• Clinical neurophysiology (40)
• Coma and raised intracranial pressure (29)
• Cranial nerves (107)
• Dementia (7)
• Drugs: CNS (not psychiatric) (33)
• Epilepsy and seizures (116)
• Headache (including migraine) (9)
• Hydrocephalus (22)
• Infection (neurology) (166)
• Motor neurone disease (14)
• Movement disorders (other than Parkinsons) (63)
• Multiple sclerosis (19)
• Muscle disease (40)
• Neuroimaging (396)
• Neurological injury (71)
• Neuromuscular disease (77)
• Neurooncology (116)
• Neuroophthalmology (8)
• Pain (neurology) (47)
• Parkinson's disease (7)
• Peripheral nerve disease (84)
• Sleep disorders (neurology) (8)
• Spinal cord (105)
• Stroke (239)
• Trauma CNS / PNS (40)
• Variant Creutzfeld-Jakob Disease (2)
• Neurology (1607)
• Nursing (36)
• Childhood nutrition (5)
• Malnutrition (24)
• Obesity (nutrition) (17)
• Vitamins and supplements (46)
• Nutrition and metabolism (118)
• Obstetrics and gynaecology (587)
• Oncology (1477)
• Ophthalmology (761)
• Orthopaedics (371)
• Adolescent health
• Bilirubin disorders (9)
• Child abuse (6)
• Child and adolescent psychiatry (paedatrics) (9)
• Child health
• Childhood nutrition (paediatrics) (7)
• Congenital disorders (280)
• Developmental paediatrics (4)
• Failure to thrive (19)
• Infant health (32)
• Infant nutrition (including breastfeeding) (5)
• Materno-fetal medicine (72)
• Neonatal and paediatric intensive care (96)
• Neonatal health (93)
• Paediatrics (876)
• End of life decisions (palliative care) (14)
• Pain (palliative care) (8)
• Palliative care (37)
• Chemical pathology
• Cytopathology
• Histopathology
• Inflammation
• Microbiology
• Molecular biology
• Morbid anatomy / surgical pathology
• Neuropathology
• Pathology (572)
• Drug misuse (including addiction) (33)
• Medicines regulation
• Toxicology (56)
• Unwanted effects / adverse reactions (311)
• Pharmacology and therapeutics (477)
• Prison medicine (1)
• Adjustment disorders
• Alcohol-related disorders (4)
• Anxiety disorders (including OCD and PTSD) (18)
• Child and adolescent psychiatry (11)
• Delirium (17)
• Drugs misuse (including addiction) (27)
• Drugs: psychiatry (29)
• Eating disorders (7)
• Impulse control disorders (6)
• Memory disorders (psychiatry) (22)
• Mood disorders (including depression) (33)
• Personality disorders (2)
• Psychiatry of old age (8)
• Psychotherapy (14)
• Psychotic disorders (incl schizophrenia) (37)
• Sexual and gender disorders (2)
• Sleep disorders (2)
• Somatoform disorders (6)
• Suicide (psychiatry) (7)
• Psychiatry (221)
• Radiology (871)
• Continuing medical education
• Disability (17)
• Other rehabilitative therapies
• Physiotherapy (41)
• Rehabilitation medicine (84)
• Acute renal failure (107)
• Chronic renal failure (49)
• Dialysis (61)
• Fluid electrolyte and acid-base disturbances (78)
• Nephrotic syndrome (29)
• Proteinurea (29)
• Renal transplantation (48)
• Renal medicine (369)
• Respiratory medicine (615)
• Ankylosing spondylitis (2)
• Biological agents (37)
• Connective tissue disease (97)
• Degenerative joint disease (9)
• Drugs: musculoskeletal and joint diseases (26)
• Fibromyalgia (2)
• Musculoskeletal syndromes (71)
• Osteoarthritis (13)
• Osteoporosis (11)
• Rheumatoid arthritis (40)
• Sjogren's syndrome (3)
• Systemic lupus erythematosus (60)
• Vascularitis (161)
• Rheumatology (569)
• Sexual health (102)
• Sports and exercise medicine (123)
• Breast surgery (69)
• Cardiothoracic surgery (205)
• Gastrointestinal surgery (432)
• General surgery (457)
• Neurosurgery (204)
• Oral and maxillofacial surgery (142)
• Orthopaedic and trauma surgery (235)
• Otolaryngology / ENT (246)
• Plastic and reconstructive surgery (177)
• Surgical oncology (230)
• Transplantation (61)
• Urological surgery (183)
• Vascular surgery (192)
• Surgery (2573)
• Urology (273)
• Communication
• Clinical trials (epidemiology)
• Epidemiologic studies
• Population trends
• Screening (epidemiology)
• Survey techniques
• Therapeutic trials
• Time-to-event methods
• Artificial and donated transplantation
• Assisted dying
• Clinical ethics
• Codes of professional ethics
• Competing interests (ethics)
• Confidentiality
• Drug issues
• End of life decisions (ethics)
• Ethics of abortion
• Ethics of reproduction
• Experiments in vivo
• Informed consent
• Research and publication ethics
• Sexuality / gender
• Ethics (16)
• Ethnic studies (2)
• Health economics (7)
• Information management
• Telemedicine
• Health policy
• Health service research
• Journalology
• Legal and forensic medicine
• Choosing / changing career
• Combining life and work
• Continuous professional development
• Flexible training
• Getting and changing jobs
• Getting and changing jobs (including job descriptions and contracts)
• Leaving medicine
• Medical careers
• Organise and prepare your CV
• Organise working abroad
• Pay, working conditions, and health
• Personal development
• Portfolio development
• Prepare for appraisal
• Prepare for interview
• Professional conduct and regulation
• Professional regulation and standards
• History taking and the physical examination
• Postgraduate
• Undergraduate
• Medical education (108)
• Doctors' morale and well being
• Medical error/ patient safety
• Quality improvement
• Medical management (208)
• Occupational and environmental medicine (141)
• Abuse (child, partner, elder)
• Air pollution
• Drug misuse
• Environmental issues
• Health education
• Health of indigenous peoples
• Health promotion
• Housing and health
• Human rights
• Obesity (public health) (5)
• Screening (public health)
• Sexual health (public health)
• Social conditions and disease
• Suicide (public health)
• Urban health
• Vaccination programs
• Violence (other)
• Violence against women
• Public health (68)
• Smoking and tobacco (16)
• Sociology (1)
• Comparative effectiveness research
• Qualitative research
• Quantitative research
• Statistics and research methods (1)
• 10-Minute Consultation
• Assessment of older adults
• BMJ clinical evidence summaries
• Care of older people
• Change page
• Clinical evidence
• Clinical governance in primary care
• Clinical guidelines (the theory)
• Clinical Update
• Competent novice
• Complexity science
• Conflict and health
• Coping with loss
• Data campaign
• Diagnosis in general practice
• Digital theme issue: Overdiagnosis
• Drug points
• E-cigarettes
• Easily missed
• Economics notes
• Ethical debates
• Evidence base of clinical diagnosis
• Evidence based case report
• Evidence based management of hypertension
• Evidence based paediatrics
• Extracts from BestTreatments
• For and against (controversies in management)
• Getting research findings into practice
• Guideline summaries
• Health needs assessment
• How does it work?
• If I ruled the NHS
• Improving the quality of health care
• Interactive case reports
• Investigation
• Lesson of the week
• Making a difference
• Managing demand
• Maternal, child, and adolescent health
• Measuring quality of life
• Methods in health services research
• Mid Staffordshire Inquiry
• Modernising the NHS
• Multimorbidity
• Narrative based medicine
• Non-communicable diseases
• Patient authored
• Patient journeys
• Pharmacology
• Practice pointer
• Pregnancy plus
• Primary care groups
• Qualitative research in health care
• Quality improvement report
• Rapid Recommendation
• Rational imaging
• Rational testing
• Regulating nursing homes
• Research pointers
• Safety alerts
• Science, medicine, and the future
• Scrap the Cap
• Seven day NHS
• Shared decision making
• Spotlight on climate change
• State of the Art
• Statistics notes
• Systematic reviews in health care
• Teaching rounds
• The BMJ Awards 2015
• The World Bank and world health
• Theories in health care and research
• Therapeutics
• Too much medicine
• UK general election 2015
• Uncertainties page
• Understanding controlled trials
• What the educators are saying
• What your patient is thinking
• What's new this month in BMJ Journals
• When I use a word
• Access to health care (9)
• Adverse drug reactions and complications (328)
• Corrections
• Determinants of health (2)
• Findings that shed new light on the possible pathogenesis of a disease or an adverse effect (256)
• Global health (71)
• Health in vulnerable communities (12)
• Images in... (2250)
• Learning from errors (76)
• Learning from unexpected outcome (positive or negative) (146)
• Medical student electives
• Medicine in the humanitarian sector
• Myth exploded
• New disease (44)
• Novel diagnostic procedure (55)
• Novel treatment (new drug/intervention; established drug/procedure in new situation) (393)
• Other full case
• Rare disease (2616)
• Reminder of important clinical lesson (714)
• Rural medicine
• Unexpected outcome (positive or negative) including adverse drug reactions (219)
• Unusual association of diseases/symptoms (708)
• Unusual presentation of more common disease/injury (792)
• Video reports
• COVID-19 (548)
• Editor's choice (66)
• Anaesthetics and ITU
• Anatomy quiz
• Case report
• Case Review
• Case scenario
• Drugs and therapeutics
• Emergency medicine
• Endocrinology
• Gastroenterology
• General practice
• Haematology
• Histopathology/cytology/pathology/autopsy
• Infectious diseases
• Law and ethics
• Learning disabled
• onExamination questions
• Ophthalmology
• Orthopaedics and trauma
• Paediatrics
• Picture quiz
• Renal medicine
• Respiratory
• Rheumatology
• Spot Diagnosis
• GUT Recent advances in clinical practice
• GUT Snapshot
• IP Cochrane corners
• JCP Education
• JECH Gallery
• JMG Online mutation reports
• Open access (793)
• Animal Models
• Biomarker Studies
• Childhood Lupus
• Clinical Trials and Drug Discovery
• Co-morbidities
• Cutaneous Lupus
• Epidemiology and Outcomes
• Immunology and Inflammation
• Lupus Nephritis
• Reproductive Health and APS
• Quality Improvement Reports

Description

NRNP 6552 Week 3 Case Study Discussion 2023 semester 1 Gynecologic Health Contraception Elaine Goodwin Well Elaborated A+ Elaine Goodwin is a 38-year-old G5 P5 LC 6 presenting to your clinic today to discuss contraceptive options. She states that she is not interested in having more children but her new partner has never fathered a child. Her medical history is remarkable for exercise-induced asthma, migraines, and IBS. Her surgical history is remarkable only for tonsils as a child. Her social history is negative for alcohol, tobacco, and recreational drugs. She has no known drug allergies and takes only vitamin C. Hospitalizations were only for childbirth. Family history reveals that her maternal grandmother is alive with dementia, while her maternal grandfather is alive with COPD. Her paternal grandparents are both deceased due to an automobile accident. Her mother is alive with osteopenia and fibromyalgia, and her dad is alive with a history of skin cancer (basal cell). Elaine has one older sister with no medical problems and one younger brother with no reported medical problems

Recommended for you

Nrnp 6552 week 3 case study discussion 2023 semester 1 gynecologic health contraception elaine.

Item added to your cart

Masks Strongly Recommended but Not Required in Maryland, Starting Immediately

Due to the downward trend in respiratory viruses in Maryland, masking is no longer required but remains strongly recommended in Johns Hopkins Medicine clinical locations in Maryland. Read more .

• Vaccines  
• Masking Guidelines
• Visitor Guidelines  

Center for Bloodless Medicine and Surgery

Case study: obstetrics and gynecology, embolization to treat uterine fibroids with bleeding and severe anemia.

A 45-year old female Jehovah’s Witness patient with a history of uterine fibroids and severe menorrhagia presented with shortness of breath, fatigue and weakness. She also had a history of deep venous thrombosis (DVT) and pulmonary emboli (PE). She was admitted with iron-deficient anemia for workup and treatment. 

After a Hematology consult, the Coumadin she had been taking for her DVT/PE history was discontinued. Gynecology was consulted and she was diagnosed with multiple large fibroids after a transvaginal ultrasound examination. It was determined that a hysterectomy may be needed, but her 3.8 g/dL hemoglobin level upon admission was too low for surgery. She was started on Lupron (Leuprolide acetate), a long acting (depot) injection medication that suppresses secretion of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and is thereby helpful in cessation of hemorrhage from uterine fibroids. She was also started on daily, intravenous 200 mg iron sucrose, and was given darbepoetin alpha 25 mcg intravenously weekly. After 3 weeks her hemoglobin level was 5.5 g/dL and she was sent home on monthly Lupron injections and oral iron supplements. She was also followed in our Hematology clinic.

Four months later she was admitted again with shortness of breath, fatigue and weakness, this time with a hemoglobin level of 3.8 g/dL. She had missed one treatment in her Lupron regimen, and had started to bleed again. Her ferritin level was 9 ng/mL (normal level for women being 18-160). On her third hospital day she was taken to interventional radiology for a uterine artery fibroid embolization. Two days later she was discharged with a hemoglobin level of 4.9 on oral iron sulfate, 325 mg twice a day. One month later on a follow up visit in the Hematology Clinic her hemoglobin level was 8.0 and she is now off of Lupron and continuing her oral iron supplements.

NRNP 6552 Week 3 Case Study 2 discussion: Gynecologic Heal... - $13.45 Add to Cart

NRNP 6552 Week 3 Case Study 2 discussion: Gynecologic Health – Contraception Elaine Goodwin

Preview 1 out of 6 pages

Generating Your Document

Purchase the document to get the full access instantly

•   3 Million+ Study Documents
•   100% Money Back Guarantee
•   Immediate Download Access

Report Copyright Violation

Available in 1 Bundle

NRNP 6552 Case Study Discussions Week 3, 4, 5, 8 and 9

$68.45 0 X Sold 6 items

Bundle contains 6 documents

Others Details

Also available in bundle from $68.45

Add To Cart

Add To Wishlist

• Trusted by 800,000+ Students
• 24/7 Money Back Guarantee
• Download is directly available

Specifications

Institution WALDEN UNIVERSITY

Study NRNP 6552

Course NRNP 6552 Week 3 Case Study 2 discussion: Gynecologic Health – Contraception Elaine Goodwin

Document Details

Language English

Subject Health Care

Updated On Dec 11,2022

Number of Pages 6

Type Others

Written 2022-2023

Seller Details

3.0K documents uploaded

277 documents sold

Member since 2 years

Reviews received

Recommended documents

NRNP 6552 Week 3 Case Stu...

what students are saying about us

DocMerit is a great platform to get and share study resources, especially the resource contributed by past students.

Northwestern University Karen

I find DocMerit to be authentic, easy to use and a community with quality notes and study tips. Now is my chance to help others.

University Of Arizona Anna Maria

One of the most useful resource available is 24/7 access to study guides and notes. It helped me a lot to clear my final semester exams.

Devry University David Smith

DocMerit is super useful, because you study and make money at the same time! You even benefit from summaries made a couple of years ago.

Liberty University Mike T

• Follow us on
• Copyright © 2024 | All rights reserved

Register a free account

• Introduction
• Conclusions
• Article Information

In both time periods, Asian and Hispanic women were underrepresented in clinical trials for all 3 cancer sites. Black women with an endometrial or cervical cancer diagnosis were either adequately represented or overrepresented in both time periods, but Black women with ovarian cancer were underrepresented. White women were adequately represented or overrepresented in clinical trials for all 3 cancer sites. Numbers were too low to generate meaningful estimates for American Indian/Alaska Native, Native Hawaiian/Pacific Islander, or other race women.

eTable 1.  International Classification of Diseases for Oncology–3 Codes Including Gynecologic Cancer Histology Types

eAppendix. Supplemental Methods

eTable 2. Participation-to-Prevalence Ratios for Women With a Gynecologic Cancer Diagnosis According to Cancer Site and Stratified by Year of Diagnosis

eReferences

Data Sharing Statement

See More About

Sign up for emails based on your interests, select your interests.

Customize your JAMA Network experience by selecting one or more topics from the list below.

• Academic Medicine
• Acid Base, Electrolytes, Fluids
• Allergy and Clinical Immunology
• American Indian or Alaska Natives
• Anesthesiology
• Anticoagulation
• Art and Images in Psychiatry
• Artificial Intelligence
• Assisted Reproduction
• Bleeding and Transfusion
• Caring for the Critically Ill Patient
• Challenges in Clinical Electrocardiography
• Climate and Health
• Climate Change
• Clinical Challenge
• Clinical Decision Support
• Clinical Implications of Basic Neuroscience
• Clinical Pharmacy and Pharmacology
• Complementary and Alternative Medicine
• Consensus Statements
• Coronavirus (COVID-19)
• Critical Care Medicine
• Cultural Competency
• Dental Medicine
• Dermatology
• Diabetes and Endocrinology
• Diagnostic Test Interpretation
• Drug Development
• Electronic Health Records
• Emergency Medicine
• End of Life, Hospice, Palliative Care
• Environmental Health
• Equity, Diversity, and Inclusion
• Facial Plastic Surgery
• Gastroenterology and Hepatology
• Genetics and Genomics
• Genomics and Precision Health
• Global Health
• Guide to Statistics and Methods
• Hair Disorders
• Health Care Delivery Models
• Health Care Economics, Insurance, Payment
• Health Care Quality
• Health Care Reform
• Health Care Safety
• Health Care Workforce
• Health Disparities
• Health Inequities
• Health Policy
• Health Systems Science
• History of Medicine
• Hypertension
• Images in Neurology
• Implementation Science
• Infectious Diseases
• Innovations in Health Care Delivery
• JAMA Infographic
• Law and Medicine
• Leading Change
• Less is More
• LGBTQIA Medicine
• Lifestyle Behaviors
• Medical Coding
• Medical Devices and Equipment
• Medical Education
• Medical Education and Training
• Medical Journals and Publishing
• Mobile Health and Telemedicine
• Narrative Medicine
• Neuroscience and Psychiatry
• Notable Notes
• Nutrition, Obesity, Exercise
• Obstetrics and Gynecology
• Occupational Health
• Ophthalmology
• Orthopedics
• Otolaryngology
• Pain Medicine
• Palliative Care
• Pathology and Laboratory Medicine
• Patient Care
• Patient Information
• Performance Improvement
• Performance Measures
• Perioperative Care and Consultation
• Pharmacoeconomics
• Pharmacoepidemiology
• Pharmacogenetics
• Pharmacy and Clinical Pharmacology
• Physical Medicine and Rehabilitation
• Physical Therapy
• Physician Leadership
• Population Health
• Primary Care
• Professional Well-being
• Professionalism
• Psychiatry and Behavioral Health
• Public Health
• Pulmonary Medicine
• Regulatory Agencies
• Reproductive Health
• Research, Methods, Statistics
• Resuscitation
• Rheumatology
• Risk Management
• Scientific Discovery and the Future of Medicine
• Shared Decision Making and Communication
• Sleep Medicine
• Sports Medicine
• Stem Cell Transplantation
• Substance Use and Addiction Medicine
• Surgical Innovation
• Surgical Pearls
• Teachable Moment
• Technology and Finance
• The Art of JAMA
• The Arts and Medicine
• The Rational Clinical Examination
• Tobacco and e-Cigarettes
• Translational Medicine
• Trauma and Injury
• Treatment Adherence
• Ultrasonography
• Users' Guide to the Medical Literature
• Vaccination
• Venous Thromboembolism
• Veterans Health
• Women's Health
• Workflow and Process
• Wound Care, Infection, Healing

Get the latest research based on your areas of interest.

Others also liked.

• Download PDF
• X Facebook More LinkedIn

Khadraoui W , Meade CE , Backes FJ , Felix AS. Racial and Ethnic Disparities in Clinical Trial Enrollment Among Women With Gynecologic Cancer. JAMA Netw Open. 2023;6(12):e2346494. doi:10.1001/jamanetworkopen.2023.46494

Manage citations:

© 2024

• Permissions

Racial and Ethnic Disparities in Clinical Trial Enrollment Among Women With Gynecologic Cancer

• 1 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Columbus
• 2 Division of Epidemiology, College of Public Health, The Ohio State University, Columbus

Question   Are there racial and ethnic disparities in clinical trial enrollment among women with gynecologic cancer?

Findings   In this cohort study of 562 592 women with endometrial, ovarian, or cervical cancer, the odds of clinical trial enrollment were lower among Asian, Black, and Hispanic women compared with White women. Comparisons with the US population demonstrated overrepresentation among White women for all cancer sites, underrepresentation among Asian and Hispanic women for all cancer sites, and varied patterns for Black women depending on cancer site.

Meaning   These findings suggest that efforts to engage women with gynecologic cancer who are from minoritized racial and ethnic groups are needed to increase their representation in clinical trials.

Importance   Racial and ethnic disparities in clinical trial enrollment are unjust and hinder development of new cancer treatments.

Objective   To examine the association of race and ethnicity with clinical trial enrollment among women with endometrial, ovarian, or cervical cancer.

Design, Setting, and Participants   This retrospective cohort study used data from the National Cancer Database, a hospital-based cancer registry, and the Surveillance, Epidemiology, and End Results Program (SEER), a population-based cancer registry. Population-based race and ethnicity–specific proportions for each cancer site were derived from SEER. Participants included women with an endometrial, ovarian, or cervical cancer diagnosed from 2004 to 2019. Analyses were performed from February 2 to June 14, 2023.

Exposure   Race and ethnicity were categorized as American Indian/Alaska Native, Asian, Black, Hispanic (any race), Native Hawaiian/Pacific Islander, White, and other (not defined in the National Cancer Database).

Main Outcomes and Measures   The primary outcomes were the odds of clinical trial enrollment and representation in clinical trials compared with the US population. Multivariable-adjusted logistic regression was used to estimate odds ratios (ORs) and 95% CIs for associations of race and ethnicity with clinical trial enrollment within the National Cancer Database sample. Participation-to-prevalence ratios (PPRs) according to diagnosis period (2004-2011 vs 2012-2019) were calculated by dividing the race and ethnicity–specific percentage of clinical trial participants in the study sample by the percentage of racial and ethnic groups in SEER.

Results   Among 562 592 patients with gynecologic cancer (mean [SD] age at diagnosis, 62.9 [11.3] years), 1903 were American Indian/Alaska Native, 18 680 were Asian, 56 421 were Black, 38 145 were Hispanic, 1453 were Native Hawaiian/Pacific Islander, 442 869 were White, and 3121 were other race and ethnicity. Only 548 (<1%) were enrolled in clinical trials. Compared with White women, clinical trial enrollment was lower for Asian (OR, 0.44; 95% CI, 0.25-0.78), Black (OR, 0.70; 95% CI, 0.50-0.99), and Hispanic (OR, 0.53; 95% CI, 0.33-0.83) women. Compared with the US population, White women were adequately or overrepresented for all cancer types (PPRs ≥1.1), Black women were adequately or overrepresented for endometrial and cervical cancers (PPRs ≥1.1) but underrepresented for ovarian cancer (PPR ≤0.6), and Asian and Hispanic women were underrepresented among all 3 cancer types (PPRs ≤0.6).

Conclusions and Relevance   In this cohort of patients with gynecologic cancer, clinical trial enrollment was lower among certain minoritized racial and ethnic groups. Continued efforts are needed to address disparate clinical trial enrollment among underrepresented groups.

Health care disparities exist within all scopes of medicine and occur along various dimensions, including race and ethnicity, socioeconomic status, geography, and language. Racial and ethnic inequities in gynecologic oncology treatment and outcomes are well-established and deeply entrenched in the social determinants of health, 1 prompting calls to address these gaps in care. 2 Clinical trials, defined as research in which humans are prospectively assigned to 1 or more interventions for the evaluation of health-related effects, 3 are essential for ensuring validity, generalizability, and equity of care, as well as advancing medical knowledge. Recent reports 4 , 5 suggest that between 6% and 8% of the US adult population with cancer participates in clinical trials, with lower representation of patients from minoritized racial and ethnic groups. Structural barriers (eg, lack of clinical trials in regions with a higher density of minoritized patients) and clinical factors (eg, narrow eligibility criteria that disproportionately affect underrepresented populations) have resulted in lower clinical trial enrollment of racial and ethnic minoritized groups, 4 with evidence that this contributes to poorer survival. 6 - 9

In a recent review, Barry and colleagues 10 outlined the extent of racial disparities in clinical trial enrollment of patients with gynecologic cancer. Most of the reviewed studies compared observed enrollment in clinical trials identified through ClinicalTrials.gov with expected enrollment derived from population-based, age-adjusted incidence rates. Collectively, women from minoritized racial and ethnic groups were underrepresented in these trials, whereas White women were more likely to be overrepresented across gynecologic cancer types. This work is an important starting point for describing racial and ethnic disparities in clinical trial enrollment of patients with gynecologic cancer; however, studies with an internal comparison group with adjustment for potential confounders are needed to fully understand the complex picture of clinical trial enrollment. Moreover, these studies highlight the need for data sets that include large numbers of women from underrepresented groups. As such, we examined associations of race and ethnicity with clinical trial enrollment among women with gynecologic cancer using the National Cancer Database (NCDB). In addition, we present participation-to-prevalence ratios (PPRs) according to period of diagnosis to evaluate trends in the representation status of underrepresented groups in gynecologic cancer trials.

The 2020 Participant User File was obtained from the hospital-based NCDB, 11 a cancer registry capturing 70% of cancers diagnosed in the US. Data include sociodemographic characteristics, tumor characteristics, treatment facility attributes, treatment, and survival outcomes abstracted from patient medical records by Certified Tumor Registrars. 12 Data submitted to NCDB undergo rigorous quality checks according to American College of Surgeons standards. This study was exempt from the Ohio State University institutional review board and the need for informed consent because the data were anonymous and publicly available, in accordance with 45 CFR §46. We followed the Strengthening the Reporting of Observational Studies in Epidemiology ( STROBE ) reporting guidelines for cohort studies. 13

We used International Classification of Disease for Oncology, Third Edition primary site codes to identify women (aged ≥18 years) with 1 of the following gynecologic cancers diagnosed between 2004 and 2019: endometrial (C54.0-C54.9 and C55.9), cervical (C53.0, C53.1, C53.8, and C53.9), ovarian (C56.9), fallopian tube (C57.0), peritoneal (C48.1 and C48.2), and retroperitoneal (C48.0). 11 , 12 We restricted the sample to common histologic types (eTable 1 in Supplement 1 ), resulting in an initial sample size of 1 018 044 women. We excluded women for the following reasons: unknown race (51 384 women), unknown facility location or type (60 441 women), unknown income or education level (105 963 women), unknown clinical trial enrollment (71 women), noninvasive or unknown cancer stage (111 827 women), unknown radiation treatment (17 330 women), unknown chemotherapy (8019 women), and unknown follow-up time (341 women). Additional cancer site-specific exclusions are detailed in the eAppendix in Supplement 1 . Following exclusions, ovarian, peritoneum, retroperitoneum, and fallopian tube cancers were grouped together for analysis.

We categorized women as enrolled in a clinical trial when response observations were enrolled in an institutional (code 2) or double-blind clinical trial (code 3). Categories of no trial (code 0), other (code 1), other–unproven (code 6), or refused trial (code 7) were categorized as no clinical trial enrollment. 14

Race and ethnicity were available as self-reported variables coded by the NCDB. We cross-classified race (American Indian/Alaska Native, Asian, Black, Native Hawaiian/Pacific Islander, White, and other) and ethnicity (Hispanic vs non-Hispanic) to produce the following categories: non-Hispanic Asian (hereafter referred to as Asian), non-Hispanic American Indian/Alaska Native (hereafter referred to as American Indian/Alaska Native), non-Hispanic Black (hereafter referred to as Black), Hispanic ethnicity of any race, non-Hispanic Native Hawaiian/Pacific Islander (hereafter referred to as Native Hawaiian/Pacific Islander), non-Hispanic White (hereafter referred to as White), and non-Hispanic other (hereafter referred to as other ). The NCDB does not specify what groups are included in “other race.” Detailed information on the categories of race that compose the 6 overarching groups is provided in the eAppendix in Supplement 1 .

Additional covariates included age at diagnosis (continuous), Charlson-Deyo comorbidity score (0, 1, or ≥2), health insurance (none, private, Medicaid, Medicare, other government), area-level annual income (<$46 277, $46 277-$57 856, $57 857-$74 062, and ≥$74,063), area-level educational attainment (measure of the percentage of adults who did not graduate from high school; ≥15.3%, 9.1%-15.2%, 5.0%-9.0%, and <5.0%), metropolitan status (large metropolitan county [population >1 million], medium metropolitan county [population 250 000-1 million], small metropolitan county [population <250,000], urban, and rural), facility location (Northeast, Midwest, Mountain, Pacific, and South), facility type (community cancer, comprehensive community cancer, academic or research, and integrated network cancer), surgery (yes or no), chemotherapy (yes or no), radiation (yes or no), cancer stage (I, II, III, and IV), and tumor grade (1, 2, or 3; applicable for uterine and ovarian endometrioid and ovarian serous only). Additional details regarding area-level income, area-level education, metropolitan status, and cancer stage are provided in the eAppendix in Supplement 1 .

In the NCDB sample, we used multivariable logistic regression to estimate adjusted odds ratios (ORs) and 95% CIs for associations of race and ethnicity with clinical trial enrollment. Factors included as covariates comprised patient, facility, tumor, and treatment characteristics that have been identified as factors related to clinical trial enrollment among patients with cancer 4 and were available in NCDB.

To evaluate the racial and ethnic composition of patients with gynecologic cancer enrolled in clinical trials (in the NCDB) relative to the racial distribution in the overall cancer-specific population, we calculated the PPR according to period of diagnosis (2004-2011 vs 2012-2019). 15 The PPR was calculated by dividing the race-specific percentage of clinical trial participants in the study sample (eg, percentage of NCDB patients with endometrial cancer enrolled in clinical trials who are Black) by the percentage of racial and ethnic groups in the US patient population (eg, percentage of US patients with endometrial cancer who are Black) according to cancer site. We used the Surveillance, Epidemiology, and End Results *Stat program to derive population-based race and ethnicity frequencies for each cancer site. We omitted calculations for American Indian/Alaska Native, Native Hawaiian/Pacific Islander, and other women owing to low numbers. Stratification of the PPR by diagnosis period (2004-2011 vs 2012-2019) was done to qualitatively assess clinical trial enrollment over time. We evaluated only 2 time periods to reduce the potential for small numbers. PPRs less than 0.8 can be interpreted as underrepresentation in clinical trials, PPRs of 0.8 to 1.2 indicate adequate representation in clinical trials, and PPRs greater than 1.2 indicate overrepresentation. 15 Additional methodological details are presented in the eAppendix in Supplement 1 .

Statistical analyses were performed using Surveillance, Epidemiology, and End Results *Stat software version 8.4.1.1 (National Cancer Institute) and SAS statistical software version 9.4 (SAS Institute). All P values were 2 sided, with statistical significance set at P < .05. Analyses were performed from February 2 to June 14, 2023.

Among 562 592 women included (mean [SD] age at diagnosis, 62.9 [11.3] years), 1903 were American Indian/Alaska Native, 18 680 were Asian, 56 421 were Black, 38 145 were Hispanic, 1453 were Native Hawaiian/Pacific Islander, 442 869 were White, and 3121 were other race and ethnicity. Only 548 women (<1%) were enrolled in a clinical trial. In a multivariable-adjusted model, compared with White women, clinical trial enrollment was lower among Asian (OR, 0.44; 95% CI, 0.25-0.78), Black (OR, 0.70; 95% CI, 0.50-0.99), and Hispanic (OR, 0.53; 95% CI, 0.33-0.83) women but not significantly different for American Indian/Alaska Native (OR, 1.37; 95% CI, 0.43-4.36), Native Hawaiian/Pacific Islander (OR, 0.86; 95% CI, 0.12-6.16), or other race (OR, 0.48; 95% CI, 0.12-1.92) women ( Table ).

We also observed that older age at diagnosis (OR per 5-year increment, 0.89; 95% CI, 0.85-0.94) and having 2 or more comorbidities (OR, 0.56; 95% CI, 0.34-0.95) were associated with lower clinical trial enrollment odds. Area-level characteristics were related to clinical trial enrollment. Women living in zip codes with higher area-level income (quartile 4 vs quartile 1, OR, 0.65; 95% CI, 0.45-0.94) or living in zip codes with lower area-level educational attainment (quartile 4 vs quartile 1, OR, 0.41; 95% CI, 0.28-0.59) had lower odds of clinical trial enrollment. Clinical trial enrollment was lower among women living in small metropolitan (OR, 0.70; 95% CI, 0.49-0.99), medium metropolitan (OR, 0.73; 95% CI, 0.58-0.93), or urban (OR, 0.70; 95% CI, 0.51-0.96) counties but not different for women in rural counties (OR, 1.10; 95% CI, 0.55-2.16) compared with women residing in large metropolitan counties. Facility characteristics were related to clinical trial enrollment. Compared with treatment in the Northeast, those treated in the South (OR, 0.72; 95% CI, 0.57-0.90), Midwest (OR, 0.68; 95% CI, 0.53-0.87), or Pacific (OR, 0.71; 95% CI, 0.52-0.97) had lower clinical trial enrollment odds. Treatment at an academic or research program (OR, 6.26; 95% CI, 2.33-16.84) or an integrated network cancer program (OR, 2.93; 95% CI, 1.07-8.05) was associated with higher clinical trial enrollment odds compared with treatment at community cancer programs.

Over the study period, we observed higher clinical trial enrollment, with women who received a diagnosis between 2016 and 2019 being approximately 10 times more likely to be enrolled compared with those who received a diagnosis between 2004 and 2006 (OR, 10.18; 95% CI, 6.32-16.39). Patients with ovarian (OR, 3.70; 95% CI, 2.69-5.08) or cervical (OR, 4.30; 95% CI, 2.76-6.70) cancer were more likely to be enrolled in clinical trials than patients with endometrial cancer. Treatment with surgery (OR, 2.77; 95% CI, 1.94-3.96) or chemotherapy (OR, 2.78; 95% CI, 1.93-4.02) was associated with increased clinical trial enrollment odds, whereas women treated with radiation were less likely to be enrolled (OR, 0.63; 95% CI, 0.43-0.92).

PPRs according to race and ethnicity and diagnosis period and stratified by cancer site are shown in the Figure . Among patients with endometrial cancer, White and Black women were adequately represented or overrepresented (PPRs ≥1.1) in clinical trials in both time periods, with a slight decline in representation among Black women between the 2 time periods (2004-2011, PPR = 1.4; 2012-2019, PPR = 1.1). Asian and Hispanic women were inadequately represented during both time periods (PPRs ≤ 0.5). Among patients with ovarian cancer, White women were overrepresented during both time periods, whereas Asian, Black, and Hispanic women were underrepresented during both periods (PPRs ≤ 0.6). For cervical cancer, Black and White women were either overrepresented or adequately represented during both time periods, whereas Asian and Hispanic women were underrepresented. Further details of the PPRs are shown in eTable 2 in Supplement 1 .

In this retrospective cohort study of women with gynecologic cancer, we used 2 complementary approaches to evaluate racial and ethnic disparities in clinical trial enrollment. First, we examined clinical trial enrollment odds comparing participation among minoritized women with that of White women, with covariate adjustment. These analyses demonstrated lower clinical trial enrollment odds among Asian, Black, and Hispanic women compared with White women, but no difference in enrollment among American Indian/Alaska Native, Native Hawaiian/Pacific Islander, or other race women. In addition, social determinants of health, including area-level income and education, geographic region, and metropolitan status, along with certain facility characteristics, were associated with clinical trial enrollment. In the second analytic approach, analyses comparing the race-specific prevalence of clinical trial enrollment in the NCDB sample with the race-specific cancer prevalence in the US population with gynecologic cancer revealed interesting patterns. First, regardless of diagnosis period, Asian and Hispanic women with an endometrial, ovarian, or cervical cancer were underrepresented in clinical trials compared with the proportion expected on the basis of US cancer incidence. White women were either adequately represented or overrepresented for all 3 cancer sites, whereas patterns diverged for Black women: among those with endometrial or cervical cancer, adequate representation or overrepresentation was noted but among those with ovarian cancer, underrepresentation was evident. Together, these analyses provide novel information on the landscape of racial and ethnic disparities in gynecologic cancer treatment.

Prior studies 7 , 8 examining clinical trial representation among patients with gynecologic cancer have compared observed case counts of racial and ethnic groups from published trials (including trials registered through ClinicalTrials.gov, Gynecologic Oncology Group–based trials, 9 or National Cancer Institute–sponsored gynecologic cancer treatment trials 16 ) to the expected racial and ethnic count obtained from population-based age-adjusted incidence rates. In support of this body of work, we identified adequate representation or overrepresentation in clinical trials among White women with endometrial, ovarian, or cervical cancers along with underrepresentation of Black patients with ovarian cancers. Our findings that Black women with endometrial or cervical cancers were adequately or overrepresented in clinical trials are in line with the findings of 2 prior studies. 8 , 16 For example, Mattei and colleagues 8 reported that Black women with either a uterine or cervical cancer were proportionately enrolled in precision medicine trials, whereas Mishkin and colleagues 16 similarly noted no enrollment disparities for Black women with uterine or cervical cancer in National Cancer Institute–sponsored treatment trials. However, an evaluation of racial representation in Gynecologic Oncology Group–sponsored clinical trials revealed that enrollment of Black women was 9.8-fold lower than expected for endometrial cancer trials and 4.5-fold lower for cervical cancer trials. 9 Overall, although our PPR findings indicate that Black women are being enrolled in endometrial and cervical cancer clinical trials at levels proportionate to their distribution in the population, this practice of striving for proportional enrollment is unlikely to culminate in the sample sizes needed to make well-powered conclusions about treatment efficacy within minoritized groups. 17 Indeed, recent calls for equitable clinical trial inclusion suggest the need to recruit equal numbers of racial and ethnic groups, such that minoritized groups are overenrolled with respect to their size in the general population. A shift in this direction would allow ideally powered analyses of treatment effects within racial and ethnic groups. 18

Disparities between Black and White populations in gynecologic oncology have been frequently investigated; however, reports focused on other racial and ethnic groups are less common. Our PPR and logistic regression analyses showing underrepresentation and lower clinical trial enrollment odds of Asian and Hispanic women agree with data published by Mattei and colleagues, 8 where women in these groups were less commonly enrolled to precision oncology trials for ovarian and uterine cancer, with Hispanic women also less likely to be enrolled in cervical cancer clinical trials. Furthermore, in a review of National Cancer Institute–sponsored gynecologic oncology trials, Hispanic, but not Asian, women were less likely to be enrolled in ovarian, uterine, or cervical cancer clinical trials. 16 Because of the low numbers of Native Hawaiian/Pacific Islander, American Indian/Alaska Native, and other race patients, we were unable to provide meaningful estimates of clinical trial enrollment odds or PPRs for these groups.

Apart from race and ethnicity, other factors associated with clinical trial enrollment included the presence of comorbidities, which was related to lower odds of clinical trial enrollment, in line with prior work. 19 Although clinical trials traditionally exclude patients with medical comorbidities under the auspice of patient safety, in 2017 and 2021, the American Society for Clinical Oncology recommended broadening clinical trial eligibility to maximize generalizability. 20 , 21 In addition, older age; living in zip codes with higher income; living in zip codes with lower educational attainment; living in urban, small, or medium sized counties; and treatment in the South, Midwest, and Pacific (compared with the Northeast) were associated with lower clinical trial enrollment. Treatment at an academic or research program or an integrated network cancer program was associated with higher odds of clinical trial enrollment. Most of these associations were expected on the basis of prior literature 22 , 23 ; however, our finding that women living in areas with higher area-level income were less likely to participate in clinical trials was surprising. It is likely that area-level income also captures unmeasured neighborhood effects underlying this unexpected association. Future studies that also include individual-level income measures will be useful in contextualizing this association.

Our analyses are limited by the available data within the NCDB, because we lack information on important patient and oncologic characteristics. Certain data that can affect clinical trial enrollment, including trial phase sponsor or funding source, availability of clinical trials, trial treatments (and whether they ultimately ended up becoming standard of care), and physician characteristics, are unavailable. As such, unmeasured confounding is possible in this observational study. In addition, the NCDB does not provide contextual information on the specific therapeutic area of the clinical trial (eg, cardiovascular, endocrine, or oncology); however, we assumed that an indication of clinical trial enrollment pertained to patients’ gynecologic cancer diagnosis. Moreover, we lacked details that would allow us to assess racial and ethnic differences in the pathway to clinical trial enrollment, which is important for clarifying the required intervention. For example, if racial and ethnic differences in clinical trial recommendations are apparent, technology-based interventions that screen patients and automate trial matching might be warranted. 24 Alternatively, if we were to observe that women from minoritized racial and ethnic groups are more likely to reject clinical trials when offered, this might suggest a need for interventions aimed at the patient and physician levels to increase participation. Furthermore, because of missing values of key variables (eg, race and stage) within the NCDB data set, we excluded approximately 45% of the original sample to conduct a complete case analysis. This approach restricted the sample size, likely leading to imprecise estimates for American Indian/Alaska Native and Native Hawaiian/Pacific Islander women. It is imperative that future studies include women from these underrepresented groups to better define clinical trial disparities.

Despite these limitations, several important strengths warrant mention. First, we used a large cancer database to examine clinical trial enrollment, which is an infrequent event. Second, our analysis allowed for an internal comparison of women from different racial and ethnic groups with control for important covariates. Third, we relied on the PPR to frame representation, as opposed to age-adjusted incidence rates, which typically do not adjust for hysterectomy status, thus allowing for a potentially more accurate estimation.

In this cohort study of women with gynecologic cancer, we observed that Asian, Black, and Hispanic women had lower odds of being enrolled in clinical trials, whereas women from other minoritized groups did not experience differences in clinical trial enrollment when compared with White women. Comparisons of clinical trial enrollment in this study sample with the US population revealed underrepresentation of Asian and Hispanic women with all 3 types of gynecologic cancers, underrepresentation of Black women with ovarian cancer, adequate representation of Black women with endometrial and cervical cancers, and overrepresentation of White women with all 3 gynecologic cancer types. Further work aimed at understanding the race-specific barriers and facilitators that impact enrollment of gynecologic oncology patients in clinical trials is imperative. Although we noted lower clinical trial enrollment in multiple minoritized groups, the pathways leading to these outcomes are likely diverse and will require targeted interventions.

Accepted for Publication: October 24, 2023.

Published: December 7, 2023. doi:10.1001/jamanetworkopen.2023.46494

Open Access: This is an open access article distributed under the terms of the CC-BY License . © 2023 Khadraoui W et al. JAMA Network Open .

Corresponding Author: Ashley S. Felix, PhD, Division of Epidemiology, College of Public Health, The Ohio State University, 1841 Neil Ave, Cunz Hall 304, Columbus, OH 43210 ( [email protected] ).

Author Contributions: Dr Felix had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Khadraoui, Backes, Felix.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Khadraoui, Meade, Felix.

Critical review of the manuscript for important intellectual content: All authors.

Statistical analysis: Meade, Felix.

Supervision: Backes, Felix.

Conflict of Interest Disclosures: Dr Backes reported receiving grants and personal fees from Merck, ImmunoGen, Clovis, and Eisai; grants from Beigene and Natera; and personal fees from CEC Oncology, AstraZeneca, GlaxoSmithKline, Agenus, UpToDate , Genentech, and Myriad outside the submitted work. Dr Felix reported receiving grants from the National Cancer Institute during the conduct of the study that were unrelated to the scope of work in this study. No other disclosures were reported.

Data Sharing Statement: See Supplement 2 .

• Register for email alerts with links to free full-text articles
• Access PDFs of free articles
• Manage your interests
• Save searches and receive search alerts

• NRNP 6552 Advanced Nurse Practice in Reproductive Health Care
• All courses

NRNP 6552 Week 3 Case Study Discussion: Gynecologic Health – Contraception Elaine Goodwin

(NRNP 6552 Week 3 Case Study, NRNP 6552 Week 3 Case Study )

Elaine Goodwin is a 38-year-old G5 P5 LC 6 presenting to your clinic today to discuss contraceptive options. She states that she is not interested in having more children but her new partner has never fathered a child. Her medical history is remarkable for exercise-induced asthma, migraines, and IBS. Her surgical history is remarkable only for tonsils as a child. Her social history is negative for alcohol, tobacco, and recreational drugs. She has no known drug allergies and takes only vitamin C. Hospitalizations were only for childbirth. Family history reveals that her maternal grandmother is alive with dementia, while her maternal grandfather is

alive with COPD. Her paternal grandparents are both deceased due to an automobile accident. Her mother is alive with osteopenia and fibromyalgia, and her dad is alive with a history of skin cancer (basal cell). Elaine has one older sister with no medical problems and one younger brother with no reported medical problems.

     Height 5’ 7” Weight 148 (BMI 23.1), BP 118/72 P 68

• Neck: supple without adenopathy
• Lungs/CV: wnl
• Breast: soft, fibrocystic changes bilaterally, without masses, dimpling or discharge
• Abd: soft, +BS, no tenderness
• VVBSU: wnl, except 1stdegree cystocele
• Cervix: firm, smooth, parous, without CMT
• Uterus: RV, mobile, non-tender, approximately 10 cm,
• Adnexa: without masses or tenderness

Related Products

Nrnp-prac 6552 coursework week 1 - 11, nrnp 6552 coursework week 1 - 11, nrnp 6552 case study discussions week 3, 4, 5, 8 and 9, prac 6552 coursework week 1 - 11, nrnp 6552 exams: knowledge check, midterm exam, final exam (bundle), nrnp 6552 exam: midterm exam plus final exam (bundle), nrnp 6552 knowledge check week 2, 5, 8 and 10 (100% correct collection), nrnp 6552 week 1 discussion: different roles of the nurse practitioner (2 versions), prac 6552 week 1 assignment 1, assignment 2, assignment 4, learning resources (bundle), nrnp 6552 week 2 assignment: taking a health history: building a health history: asking difficult questions (assigned due in week 2), prac 6552 week 2 assignment 2: practicum experience plan, nrnp 6552 week 2 knowledge check (100% correct collection), nrnp 6552 week 3 case study discussion: gynecologic health - charlene baja, prac 6552 week 3 assignment 2: episodic visit: gynecology focused note, nrnp 6552 week 4 case study discussion: common gynecologic conditions, part 1 - missing period, nrnp 6552 week 4 case study discussion: common gynecologic conditions, part 1 - sti investigation, nrnp 6552 week 5 knowledge check (collection), nrnp 6552 week 5 case study: common gynecologic conditions part 2, prac 6552 week 5 assignment 2: journal entry #1 (3 versions), nrnp 6552 week 6 midterm exam collection, nrnp 6552 week 6 midterm answers (april qtr), nrnp 6552 week 6 midterm solutions (summer qtr), nrnp 6552 week 6 midterm exam (fall session), nrnp 6552-19 week 6 midterm exam (july qtr), prac 6552 week 7 assignment: agpcnp students episodic visit common gynecologic health conditions (2 versions), prac 6552 week 7 assignment 2: fnp students ob episodic visit: focused note, nrnp 6552 week 7 discussion: health conditions and implications for women, nrnp 6552 week 8 case study discussion: common health conditions with implications for women, nrnp 6552 week 8 knowledge check (100% correct collection), nrnp 6552 week 9 case study discussion: working through ethical dilemmas and other issues in advanced nursing practice, nrnp 6552 module 4 week 10 knowledge check (collection), prac 6552 week 10 assignment 2: journal entry #2, prac 6552 week 10 assignment 3: comprehensive well women exam (2 verions), nrnp 6552 week 11 final exam review (completed), nrnp 6552 week 11 final exam (fall session), leave a reply cancel reply.

Your email address will not be published. Required fields are marked *

StudyExcell

Case Study Discussion: Gynecologic Health

Pssst… we can write an original essay just for you.

Any subject. Any type of essay. We’ll even meet a 3-hour deadline.

writers online

Institutional affiliation

Part I: Additional information Needed

There is additional information that the healthcare provider can inquire from Elaine. There is a need to ask for current medications, which involve the length of time she has been taking them, frequency, and the reasons she has been taking those medications. Besides, it is essential to identify the hobbies and occupations of Elaine Goodwin. Also, the healthcare provider must look for mental illnesses such as anxiety and depression, and lastly check if she has had any concern about violence with her current partner.

Part II: More Questions

What she has used in the past and partners in the past 12 months

From the case study, it is evident that Elaine Goodwin is not interested in having children even though her current partner doesn’t have one. As such, it implies that she has had one partner in the last year.

Description of her Current cycles

Elaine Goodwin is expected to have a regular menstrual cycle, which occurs every month and prepares her for a possible pregnancy. It will be an indication that her body is usually working. However, there will be an indication that she is not experiencing a normal period in case of irregular periods, making the healthcare provider ensure the provision of steps that will be critically important in preventing the problem.

Descriptions of Her Migraines

Her migraines are without auras, accompanied by fatigue, anxiety, depression, which occurs several hours before experiencing severe headache pain. As such, Elaine Goodwin may be experiencing an increased level of thirst, sleep, and craving. In this regard, most patients (between 70 and 75%) have a less likelihood of experiencing migraine likelihood (Wachholtz, Malone & Pargament, 2017). As such, patients like Elaine Goodwin are likely to experience migraine without aura, as it is regarded as the common, occurring form of migraine. In this regard, she is expected to experience three different phases of a migraine, which include prodrome, headaches, and postdrome phase.

Method Considered by Elaine

The World Health Organization provides that the use of Intrauterine device (IUD), sterilization, and progestin are the types of contraceptives that can effectively help prevent unwanted pregnancies, as evident by the actions of Elaine Goodwin, who is need of them (Haskins, n.d.). Goodwin is approaching the menopause period, and her partner has not fathered any child. As a result, she needs to get reversible contraception like the IUD, as she might decide to change her view in the future and get a child with her lover. However, she can also use the short-term contraceptives methods like the oral, even though it is essential to assess these options depending on an individual.

Part III: Questions

Next steps/consideration

After assessing the need for Elaine Goodwill, it is essential to take the required steps to get the best advice on her situation. In this regard, there is a need to advise her on involving her partner in this decision. There is also a need to consider the risks associated with different forms of contraception because there are many significant changes in the lives of women who are approaching menopause. In this regard, clinical judgment will be essential in balancing the risks and benefits. In this regard, the effective contraceptives that contain estrogen should be used with care, as they may predispose a woman to serious health risks. The same applies to oral contraceptives from women approaching age forty, as they are less effective.

Teaching Required

It is essential to teach Elaine Goodwin about the risk factor associated with the types of contraceptives she may desire to use (Grindlay & Grossman, 2016). Also, there is a need to educate her on the importance of using IUDs, as she may decide to change her opinion concerning getting another child with her new lover, who hasn’t fathered any kid.

Methods Appropriate for Elaine

The use of IUDs will be essential for her, as she may decide to get another child with her new partner. However, Goodwin can still use sterilization and progestin.

Grindlay, K., & Grossman, D. (2016). Prescription birth control access among US women at risk of unintended pregnancy.  Journal of Women’s Health ,  25 (3), 249-254.

Haskins, J. (n.d.).  Sex after 40: Choosing the right contraceptive . Healthline.  https://www.healthline.com/health-news/aging-the-right-contraceptive-for-older-women-030513

Wachholtz, A. B., Malone, C. D., & Pargament, K. I. (2017). Effect of different meditation types on migraine headache medication use.  Behavioral Medicine ,  43 (1), 1-8.

  Remember! This is just a sample.

Save time and get your custom paper from our expert writers.

In case you can’t find a sample example, our professional writers are ready to help you with writing your own paper. All you need to do is fill out a short form and submit an order